Takeda and Millennium Announce European Conditional Marketing Authorisation for ADCETRIS® (Brentuximab Vedotin)

31.10.2012

Osaka, Japan, and Cambridge, Mass., October 31, 2012 – Takeda Pharmaceutical Company Limited (TSE:4502, “Takeda”) and Millennium: The Takeda Oncology Company, today announced that the European Commission (EC) has granted conditional marketing authorisation for ADCETRIS® (brentuximab vedotin) for two indications: (1) the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, and (2) for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).

Read more

 

Top of page

Takeda Pharma